Stevanato Group (STVN)
Develops pharmaceutical containment, delivery, diagnostic, and manufacturing solutions for drug-development and production workflows.
Something off on this page? Send us feedback.
Supplies pharmaceutical-grade containment and delivery products, diagnostic solutions, engineering equipment, and analytical services. Its integrated platform serves pharmaceutical and biotechnology customers across development, clinical, and commercial stages, pairing technical manufacturing with a global production footprint.
Pharmaceutical-grade containment and delivery products sit alongside diagnostic solutions, engineering equipment, and analytical services. The platform spans containment, delivery, diagnostics, and manufacturing services. It supports pharmaceutical and biotechnology customers from development through clinical and commercial stages.
Manufacturing expanded from Italy to sites in Mexico, China, Brazil, and the United States; the Fishers, Indiana facility produces EZ-fill syringes and vials while supporting North American engineering after-sales work. Acquisitions added inspection-machine, diagnostic-consumable, drug-delivery, and medical-component capabilities.
The business depends on integrated product, process, and service delivery for regulated pharmaceutical and biotechnology customers.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Sep 9, 2026 | UBS | Initiate | Rating: — | |
| Mar 5, 2026 | Keybanc | Reiterate | Rating: —Target: — | Target: $32 |
| Feb 10, 2026 | Jefferies | Target | Target: — | Target: $17.50 |
| Dec 1, 2025 | Morgan Stanley | Target | Target: $22 | Target: $24 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $95.3M · Total debt $504.9M · Total assets $2.98B · Shareholders' equity $1.77B
- Revenue
- $344.2M
- Operating income
- $44.6M
- Net income
- $26.2M
Reported in EUR, converted at the latest exchange rate
HistoryDividendAnnual yield
| Institutions | 16.40% | 44.76M ADS | |
|---|---|---|---|
| 127 holders · as of Jun 30, 2026 | |||
| Other | 83.60% | 228.25M ADS | |
| remainder | |||
273.01M ADS as of Sep 20, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Some positions are filed in underlying shares, not receipts; the ratio is unknown, so no percentage.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Conestoga Capital Advisors, LLCInstitution | 2.57% | 7.01M ADS | as of Jun 30, 2026 |
Neuberger Berman Group LLCInstitution | 2.06% | 5.62M ADS | as of Jun 30, 2026 |
Timessquare Capital Management, LLCInstitution | 1.27% | 3.47M ADS | as of Jun 30, 2026 |
Van Berkom & Associates Inc.Institution | 1.09% | 2.97M ADS | as of Jun 30, 2026 |
Artisan Partners Limited PartnershipInstitution | 0.95% | 2.60M ADS | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 7, 2026 | Elisabetta Magistretti | director | −2,045 | $20.09 |
| Aug 7, 2026 | Lago Marco Dal | officer: Chief Financial Officer | −4,209 | $20.09 |
| Aug 7, 2026 | Luciano Santel | director | −2,023 | $20.09 |
| Jun 15, 2026 | William J. Federici | director | −1,493 | $17.09 |
| Jun 15, 2026 | Karen Flynn | director | −1,493 | $17.09 |
- West Pharmaceutical Services
Injectable containment, delivery-device, and CDMO rival.
- BD
Prefillable syringe and self-injection systems rival.
- ATS (ADR)
Life-sciences automation and pharmaceutical-packaging rival.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Stevanato Group | $21.09 | −2.81% | $5.92B | 39.6 | 27.1 | 4.2 | +4.6% |
| West Pharmaceutical Services | $370.89 | −0.05% | $26.12B | 47.5 | 40.1 | 7.9 | +13.9% |
| BD | $183.14 | +0.08% | $50.42B | 55.1 | 13.8 | 2.4 | −9.6% |
| ATS (ADR) | $19.22 | +0.58% | $1.87B | 56.5 | 22.3 | 0.9 | −9.7% |
| Median | 55.1 | 22.3 | 2.4 | −9.6% |